<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961360</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-1073</org_study_id>
    <nct_id>NCT03961360</nct_id>
  </id_info>
  <brief_title>Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida</brief_title>
  <acronym>ASPREO</acronym>
  <official_title>Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida: An Open Label, Comparative Effectiveness, Randomized Controlled Trial (ASPREO Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a
      singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior
      pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either
      81mg/day aspirin or 162mg/day aspirin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preeclampsia diagnosis</measure>
    <time_frame>3-7 months</time_frame>
    <description>based on American College Obstetrics and Gynecology (ACOG) guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Incidence of preterm preeclampsia</measure>
    <time_frame>less than 37 weeks gestational age (GA)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Gestational Hypertension</measure>
    <time_frame>3-7 months</time_frame>
    <description>development of hypertension anytime during pregnancy based on ACOG guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Placenta Abruption</measure>
    <time_frame>1 day</time_frame>
    <description>Placental abruption occurs when the placenta separates from the inner wall of the uterus before birth. As assessed by treating OBGYN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Eclampsia</measure>
    <time_frame>20 weeks</time_frame>
    <description>onset of seizures (convulsions) in a woman with pre-eclampsia per ACOG guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-HELLP syndrome</measure>
    <time_frame>4 weeks</time_frame>
    <description>group of symptoms that occur in pregnant women who have: hemolysis(H): (the breakdown of red blood cells)elevated liver enzymes (EL). low platelet (LP) count. Assessed by ACOG guidelines and measured in urine and blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Postpartum Hemorrhage</measure>
    <time_frame>1-24 hrs post delivery</time_frame>
    <description>excessive bleeding following the birth of a baby</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Other maternal bleeding</measure>
    <time_frame>during labor to 24 hrs post delivery</time_frame>
    <description>any other bleeding associated with birth not otherwise categorized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes-Need for blood transfusion</measure>
    <time_frame>during delivery</time_frame>
    <description>peripartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes- Gestational age at delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Delivery at &lt; 37 weeks</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Apgar score at 5 min ≤ 5</measure>
    <time_frame>5 min post delivery</time_frame>
    <description>A method to quickly summarize the health of newborn children against infant mortality Appearance, Pulse, Grimace, Activity, and Respiration. Scored from 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Small for gestational age</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Neonatal Intensive Care Unit (NICU) length of stay</measure>
    <time_frame>from birth until discharge from NICU (about 1 to 10 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Intraventricular Hemorrhage Grade III-IV</measure>
    <time_frame>from birth until discharge from NICU (about 1 to 10 weeks)</time_frame>
    <description>bleeding inside or around the ventricles in the brain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Bronchopulmonary Dysplasia</measure>
    <time_frame>from birth until discharge from NICU (about 1 to 10 weeks)</time_frame>
    <description>chronic lung disease that affects newborns (mostly premature) and infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcomes-Necrotizing Enterocolitis</measure>
    <time_frame>from birth until discharge from NICU (about 1 to 10 weeks)</time_frame>
    <description>medical condition where a portion of the bowel dies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Hypertension in Pregnancy</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>162 mg/day Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>81 mg/day Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Low dose aspirin was initially reported as having a beneficial effect at preeclampsia</description>
    <arm_group_label>81 mg/day Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 162 mg</intervention_name>
    <description>Low dose aspirin was initially reported as having a beneficial effect at preeclampsia</description>
    <arm_group_label>162 mg/day Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  A singleton gestation at less than 20 weeks at time of enrollment, with a BMI greater
             than or equal to 30 and one of the following:

             1. History of preeclampsia in a prior pregnancy

          -  Diagnosis will be obtained by review of records, and if unavailable then patient
             history. Preeclampsia diagnosis may be made in antepartum or postpartum period.

        OR 2. At least stage I hypertension during pregnancy

          -  Stage I hypertension is defined as a systolic blood pressure between 130- 139 mm Hg or
             diastolic blood pressure between 80-89 mm Hg21

          -  This blood pressure criteria is met regardless of medication usage

          -  The patient must have a blood pressure reading ≥ 130-139/80-89 mm Hg at least during 1
             clinic visit during the current pregnancy; before or at time of enrollment

        OR

        3. Pre-gestational diabetes

          -  Type 1 and Type 2 diabetics are included

          -  Gestational diabetes mellitus diagnosed prior to 20 weeks gestational age will also be
             included

        Exclusion Criteria

          -  Known allergy/prior adverse reaction/any medical condition where aspirin is
             contraindicated

          -  Already on aspirin prior to pregnancy

          -  Baseline renal Disease

          -  Baseline proteinuria identified at time of enrollment, defined as urine analysis with
             3+ protein, or urine protein to creatinine ratio ≥ 0.3

          -  Systemic Lupus Erythematosus

          -  Seizure disorder on medications

          -  HIV positive status

          -  Known major fetal anomalies

          -  Multifetal gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>farah Amro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center of Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farah Amro, MD</last_name>
    <phone>713-500-6421</phone>
    <email>farah.h.amro@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farah H Amro, MD</last_name>
      <phone>713-500-6421</phone>
      <email>farah.h.amro@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Farah Hassan Amro</investigator_full_name>
    <investigator_title>Clinical Fellow OBGYN</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

